Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates

Yokota, Shinichi; Ohkoshi, Yasuo; Fujii, Nobuhiro

doi:10.1016/j.diagmicrobio.2009.05.006

Cited by 7 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the antibiotic resistance developed among pathogenic bacteria requires permanent research into alternative preparations possessing antimicrobial effects 3, 5. Numerous novel quinolone derivatives have been synthesized, and a great deal of attention has been focused on the investigation of their physicochemical properties and biological activities 7–13. The presence of selenium in molecules can provide new properties, and some of the synthesized selenaheterocyclic compounds have demonstrated positive biological impact 14–16.…”

Section: Introductionmentioning

confidence: 99%

Anodic oxidation of selenadiazoloquinolones in alkaline media

Staško

Zalibera

Barbieriková

et al. 2011

Magnetic Reson in Chemistry

View full text Add to dashboard Cite

Newly synthesized derivatives of 6-oxo-6,9-dihydro[1,2,5]selenadiazolo[3,4-h]quinoline variously substituted at position 7 (R = H, COOH, COCH(3), CN, COOC(2)H(5) and COOCH(3)) are established in strongly alkaline aqueous solutions (0.1 M NaOH; pH ∼ 13) as N(9)-deprotonated structures, but in less alkaline solutions (0.001 M NaOH; pH ∼ 11) the N(9)-protonated oxo tautomeric forms dominate. Upon their anodic oxidation in alkaline solutions, the selenadiazole ring is replaced, forming instead the paramagnetic species analogous to the ortho semiquinone radical anions as monitored by in situ EPR spectroscopy. The quantum chemical calculations for two representative selenadiazoloquinolones (R = H and COOH) and their anodic oxidation products presented are in agreement with experiments.

show abstract

Section: Introductionmentioning

confidence: 99%

Anodic oxidation of selenadiazoloquinolones in alkaline media

Staško

Zalibera

Barbieriková

et al. 2011

Magnetic Reson in Chemistry

View full text Add to dashboard Cite

show abstract

“…However, sitafloxacin demonstrated in vitro activity against various mutant S. pneumoniae with gyrA or parC mutations and fluoroquinolone-resistant isolates with multiple mutations in gyrA, parC and/or parE. 50,64,65…”

Section: Pharmacodynamicmentioning

confidence: 99%

“…However, sitafloxacin demonstrated in vitro activity against various mutant S. pneumoniae with gyrA or parC mutations and fluoroquinoloneresistant isolates with multiple mutations in gyrA, parC and/or parE. 50,64,65 pharmacokinetics Absorption, serum protein binding and tissue distribution Nakashima et al studied the pharmacokinetics of sitafloxacin among other quinolones in healthy Japanese volunteers who received oral doses of 50 or 100 mg, a mean maximum sitafloxacin serum concentration (C max ) of 0.51 and 1 µg/mL was revealed after t max of 1.2 hours. 66 The mean area under the serum concentration-time curve (AUC) from zero to infinity was 2.62 µg ⋅ h/mL (50 mg) and 5.55 µg ⋅ h/mL (100 mg), respectively.…”

Section: Resistancementioning

confidence: 99%

Bacterial Infections in the Elderly Patient: Focus on Sitafloxacin

Ghebremedhin

2012

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

Sitafloxacin (DU-6859a) is a new-generation oral fluoroquinolone with in vitro activity against a broad range of Gram-positive and -negative bacteria, including anaerobic bacteria, as well as against atypical bacterial pathogens. Particularly in Japan this antibiotic was approved in 2008 for treatment of a number of bacterial infections caused by Gram-positive cocci and Gram-negative cocci and rods, including anaerobia atypical bacterial pathogens. As compared to oral levofloxacin sitafloxacin was non-inferior in the treatment of community-acquired pneumonia and non-inferior in the treatment of complicated urinary tract infections, according to the results of randomized, double-blind, multicentre, non-inferiority trials. Non-comparative studies demonstrated the efficacy of oral sitafloxacin in otorhinolaryngological infections, urethritis in men, cervicitis in women and odontogenic infections. Most common adverse reactions were gastrointestinal disorders and laboratory abnormalities in patients receiving oral sitafloxacin; diarrhea and liver enzyme elevations were among the common. In the Japanese population sitafloxacin covers broad spectrum of bacteria as compared to carbapenems, whereas in the Caucasians its use is currently limited due to the potential for ultraviolet A phototoxicity. Sitafloxacin is a promising therapeutic agent which merits further investigation in randomized clinical trials of elderly patients.

show abstract

“…Garenoxacin, a desfluoro(6)-quinolone, exhibits potent activity against Gram-positive bacteria [4], especially against S. pneumoniae, including quinolone-resistant strains [5]. It also possesses favourable bioavailability and pharmacokinetic profiles [6].…”

Section: Introductionmentioning

confidence: 99%